Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CytoDyn Inc.
No Price
Closing Price OTC 01.05.2026:
0,30 USD
01.05.2026 19:57
Current Prices from CytoDyn Inc.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
CYDY
USD
01.05.2026 19:57
0,30 USD
-0,008 USD
-2,71 %
Company Profile for CytoDyn Inc. Share
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
